4.7 Article Book Chapter

MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets

Journal

YEAR IN DIABETES AND OBESITY
Volume 1353, Issue -, Pages 72-88

Publisher

BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12758

Keywords

microRNAs; diabetic nephropathy; transforming growth factor beta 1; signal transduction; biomarkers; therapeutics; noncoding RNA

Funding

  1. NIDDK NIH HHS [R01 DK058191, R01 DK081705] Funding Source: Medline

Ask authors/readers for more resources

MicroRNAs (miRNAs) are short noncoding RNAs that regulate gene expression by posttranscriptional and epigenetic mechanisms and thereby affect many cellular processes and disease states. Over 2,000 human mature miRNAs have been identified, and at least 60% of all human protein-coding genes are known to be regulated by miRNAs. MicroRNA biogenesis involves classical transcription regulation and processing by key ribonucleases, as well as other protein factors and epigenetic mechanisms. Diabetic nephropathy (DN), a severe microvascular complication frequently associated with diabetes mellitus, is a major cause of renal failure. Although several mechanisms of regulation of key renal genes implicated in DN pathogenesis have been identified, a greater understanding is needed to develop better treatment modalities. Recent studies show that miRNAs induced in renal cells in vivo and in vitro under diabetic conditions can promote the accumulation of extracellular matrix proteins related to fibrosis and glomerular dysfunction. In this review, we highlight the significance of the expression of miRNAs in various stages of DN and emerging approaches to exploit them as biomarkers for early detection or novel therapeutic targets to prevent progression of DN.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available